Zbyněk Schroner, Vladimír Uličiansky
The aim of the multicenter, open-label, observational study PREDICTIVE® was to assess safety and efficacy of insulin detemir in both type 1 and 2 diabetes patients in actual clinical practice. The results of the European cohort of PREDICTIVE® after three-month therapy with insulin detemir found it to be an efficacious product allowing substitution of basal insulin secretion. Its administration was associated with a minimal occurrence of adverse events (especially major hypoglycemic episodes) together with a low within-patient fasting glucose variability and more predictable therapeutic effect. The European cohort of the PREDICTIVE® study confirmed the results of clinical randomised trials, that the therapy with insulin detemir does not cause body weight gain. Moreover, body weight reduction in type 1 and 2 diabetes patients was observed within this study. Results from the six-month insulin detemir therapy provide evidence on the long term safety and efficacy of this insulin. Results of the TITRATE® study showed, that lowering the fasting glucose target using a self-directed titration algorithm with once-daily detemir is safe and efficacious.